1. Drug Classification & Indications

Dupixent (dupilumab) is a monoclonal antibody that selectively inhibits the interleukin-4 receptor alpha (IL-4Rα), thereby blocking signaling of both IL-4 and IL-13, two key cytokines implicated in type 2 inflammation.

Indications:

• Moderate-to-severe atopic dermatitis (AD):
  • For patients aged ≥6 years who have inadequate control with topical therapies or cannot use them.
  • Approved for use as monotherapy or adjunct to topical corticosteroids, especially in those with frequent flares or steroid dependence.
  • Evidence: Multiple phase III trials (e.g., LIBERTY AD, LIBERTY ASCEND) demonstrated significant improvement in Eczema Area and Severity Index (EASI) scores and reduced use of systemic steroids.
• Moderate-to-severe Asthma:
  • For adults and children ≥6 years with uncontrolled asthma inadequately managed by standard therapies.
  • Reduces exacerbations, improves lung function, and may decrease oral corticosteroid use.
  • Evidence: LIBERTY ASThma program showed significant reductions in severe exacerbations and improved quality of life.
• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP):
  • Approved for adults only; not approved for pediatric populations under 18 years.
  • Reduces nasal symptoms, improves sinus function, and decreases need for surgery.
  • Evidence: LIBERTY CRSwNP trial showed significant improvement in nasal polyp burden and quality of life.

2. Mechanism of Action

• Dupilumab binds to the IL-4Rα subunit, preventing IL-4 and IL-13 from activating their receptors.
• This dampens Th2-mediated inflammation, reducing skin barrier dysfunction (AD), airway hyperreactivity (asthma), and chronic rhinosinusitis inflammation.

3. Dosing & Administration

Adults and Children:

• Atopic Dermatitis:
  • Initial dose: 600 mg (two 300 mg subcutaneous injections) or 400 mg (two 200 mg injections), spaced 2–4 weeks apart.
  • Maintenance: Adjust based on clinical response; may repeat every 2–4 weeks.
  • Injection Sites: Thigh, abdomen (avoid within 5 cm of navel); upper arm if administered by caregiver. Rotate sites to minimize irritation.
• Asthma:
  • Initial dose: 300 mg or 600 mg subcutaneous injection, repeated every 2–4 weeks.
  • Maintenance: Adjust per clinical response and tolerability.
• CRSwNP:
  • Two 200 mg injections (total 400 mg), then maintenance every 2–8 weeks depending on severity.

Special Considerations:

• Use pre-filled syringe or pen for ease of administration, especially in pediatric populations.
• Instruct caregivers to supervise injection site rotation and monitor for adverse reactions.

4. Pharmacovigilance & Safety Monitoring

Common Adverse Events (AEs):

• Local injection site reactions (redness, pain, swelling)
• Ocular: Conjunctivitis, blepharitis
• Upper respiratory: Sore throat, toothache, insomnia
• Gastrointestinal: Eosinophilia, gastroenteritis

Serious Adverse Events (SAEs):

• Ocular: Severe eye inflammation (uveitis, keratitis, conjunctivitis) — monitor for vision changes.
• Eosinophilic Conditions: Rare but serious eosinophilia, eosinophilic pneumonia, vasculitis (EGPA), or systemic reactions.
• Hypersensitivity: Anaphylaxis, angioedema, urticaria; discontinue if severe.
• Infections: Risk of exacerbation of chronic helminthic infections; screen and treat prior to initiation.

Drug Interactions:

• Live Vaccines: Avoid due to theoretical risk of vaccine-derived infection (e.g., MMR, varicella). Inactivated vaccines are generally safe.
• Systemic/Topical Corticosteroids: Do not abruptly withdraw; gradual dose reduction under supervision is recommended to avoid rebound symptoms or adrenal insufficiency.

5. Special Populations

• Pregnancy & Lactation:
  • No evidence of harm, but data are limited. Use only if benefit outweighs risk (FDA category C). Avoid unless clearly needed.
• Pediatrics (<6 years): Safety and efficacy not established; use only in clinical trials or with careful risk-benefit assessment.
• Elderly: No specific dosing concerns, but monitor for comorbidities and polypharmacy.

6. Counseling Points for Pharmacists

• Adherence & Technique: Ensure patient/caregiver understands injection technique, site rotation, and storage (refrigerate, do not freeze).
• Monitoring: Advise patients to report new or worsening eye symptoms, joint pain, or signs of infection promptly.
• Vaccinations: Review immunization status; avoid live vaccines during therapy.
• Drug Interactions: Counsel on avoiding live vaccines and inform all providers about Dupixent use.

7. Summary Table: Key Points for Practice

References & Guidelines

• FDA Label (Dupixent) [2024]
• American Academy of Dermatology (AAD) guidelines on AD
• Global Initiative for Asthma (GINA) 2024 recommendations
• American College of Allergy, Asthma & Immunology (ACAAI)
• UpToDate: Dupilumab in Atopic Dermatitis, Asthma, and CRSwNP

In summary:
Dupixent is a cornerstone biologic for moderate-to-severe AD, asthma, and CRSwNP. Pharmacists play a vital role in ensuring correct dosing, administration technique, patient education, and vigilant monitoring for rare but serious adverse events. Always review patient comorbidities, concomitant medications, and vaccination status before dispensing or counseling.

For further information:
Dupixent Official Website

This summary is intended for educational purposes and does not replace individualized clinical judgment.